Angiogenesis 2023: Ocular Therapeutix announces data from phase 1 clinical trial evaluating OTX-TKI for treatment of Wet AMD
Angiogenesis 2023: DERBY, OAKS clinical trials for geographic atrophy demonstrate safety, efficacy
In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.
A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.
According to investigators, the new discovery enhances our understanding of the previously unknown function of genomic regions outside the genes.
Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.
According to the company, the approval allows Eyenuk’s EyeArt AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss.
Researchers used obesity as a model to accelerate and exaggerate the stressors experienced by the body throughout life.
The study advances the understanding of the leading cause of visual impairment in adults.
The study could lead to early diagnosis and treatment of age-related macular degeneration.
Daniel F Kiernan, MD, FACS, discusses idiosyncratic biologic response to anti-VEGF treatment in a patient with neovascular AMD.
Daniel F Kiernan, MD, FACS, reviews the case of an 83-year-old male patient with neovascular AMD.
Daniel F Kiernan, MD, FACS, discusses impressions and key takeaways from a neovascular AMD patient case, focusing on treatment intervals.
Daniel F Kiernan, MD, FACS, provides an overview of a patient case of a 79-year-old female with neovascular AMD.
The researchers conducted a retrospective chart review of patients with typical exudative AMD that had been treated with anti-VEGF therapy injections.
Investigators conducted a cohort study to determine if there is a correlation between intake of nitrate and AMD progression based on previous suggestions that low nitrate levels in the diet may put patients at risk of AMD progression.
The researchers reported that there was no significant difference in the AMD prevalence among the 3 study groups.
According to investigators, the study used curated real-world data from the IRIS Registry to report risk of progression by stage.
The company said the submission follows the FDA acceptance of the ONS-5010 BLA for the treatment of wet AMD, with a PDUFA date of August 29, 2023.
Scientists from the Clear Vision Research Lab at The Australian National University and the Korean biotech company MDimune Inc. hope to turn recent research milestones into potential treatments for AMD.
The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.
Ophthalmologist discusses the impact of getting older on patients diagnosed with the disease.
Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.
Aflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.
While the advent of anti-VEGF therapies resulted in substantially better outcomes in this patient population, the results can vary substantially among patients.
Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.
This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.
